JP2007531750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007531750A5 JP2007531750A5 JP2007506468A JP2007506468A JP2007531750A5 JP 2007531750 A5 JP2007531750 A5 JP 2007531750A5 JP 2007506468 A JP2007506468 A JP 2007506468A JP 2007506468 A JP2007506468 A JP 2007506468A JP 2007531750 A5 JP2007531750 A5 JP 2007531750A5
- Authority
- JP
- Japan
- Prior art keywords
- methylamino
- composition
- dihydro
- benzoxazin
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 24
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000002193 Pain Diseases 0.000 claims 14
- 230000036407 pain Effects 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 11
- -1 alkyl sulfone Chemical group 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 8
- 241000282412 Homo Species 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 208000001640 Fibromyalgia Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 230000001457 vasomotor Effects 0.000 claims 4
- POXIKNMZDSNTEK-UHFFFAOYSA-N 1-(6-chloro-2,3-dihydro-1,4-benzoxazin-4-yl)-3-(methylamino)-1-phenylpropan-2-ol Chemical compound C1COC2=CC=C(Cl)C=C2N1C(C(O)CNC)C1=CC=CC=C1 POXIKNMZDSNTEK-UHFFFAOYSA-N 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 201000001880 Sexual dysfunction Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 3
- 230000000407 monoamine reuptake Effects 0.000 claims 3
- 231100000872 sexual dysfunction Toxicity 0.000 claims 3
- NYFIIMYTYZYJNH-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzoxazin-4-yl)-3-(methylamino)-1-phenylpropan-2-ol Chemical compound C1COC2=CC=CC=C2N1C(C(O)CNC)C1=CC=CC=C1 NYFIIMYTYZYJNH-UHFFFAOYSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 2
- 229910005965 SO 2 Inorganic materials 0.000 claims 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000001668 ameliorated effect Effects 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000009245 menopause Effects 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000009935 visceral pain Diseases 0.000 claims 2
- POXIKNMZDSNTEK-FUHWJXTLSA-N (1r,2s)-1-(6-chloro-2,3-dihydro-1,4-benzoxazin-4-yl)-3-(methylamino)-1-phenylpropan-2-ol Chemical compound C1([C@@H](N2C3=CC(Cl)=CC=C3OCC2)[C@@H](O)CNC)=CC=CC=C1 POXIKNMZDSNTEK-FUHWJXTLSA-N 0.000 claims 1
- ZXWNVYVRSLCDLQ-MJGOQNOKSA-N (1s,2r)-1-(2,2-dimethyl-3h-1,4-benzoxazin-4-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol Chemical compound C1([C@H](N2C3=CC=CC=C3OC(C)(C)C2)[C@H](O)CNC)=CC=CC(F)=C1 ZXWNVYVRSLCDLQ-MJGOQNOKSA-N 0.000 claims 1
- CUYWGZURXSNKCO-MJGOQNOKSA-N (1s,2r)-1-(2,2-dimethyl-3h-1,4-benzoxazin-4-yl)-3-(methylamino)-1-phenylpropan-2-ol Chemical compound C1([C@H](N2C3=CC=CC=C3OC(C)(C)C2)[C@H](O)CNC)=CC=CC=C1 CUYWGZURXSNKCO-MJGOQNOKSA-N 0.000 claims 1
- GEBVDAMYWOGQQG-AEFFLSMTSA-N (1s,2r)-1-(2,3-dihydro-1,4-benzothiazin-4-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol Chemical compound C1([C@H](N2C3=CC=CC=C3SCC2)[C@H](O)CNC)=CC=CC(F)=C1 GEBVDAMYWOGQQG-AEFFLSMTSA-N 0.000 claims 1
- DAQQEUNYRWDGFD-NHTMILBNSA-N (1s,2r)-1-(3-fluorophenyl)-3-(methylamino)-1-[(2r)-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl]propan-2-ol Chemical compound C1([C@@H]2CN(C3=CC=CC=C3O2)[C@H]([C@H](O)CNC)C=2C=C(F)C=CC=2)=CC=CC=C1 DAQQEUNYRWDGFD-NHTMILBNSA-N 0.000 claims 1
- DAQQEUNYRWDGFD-JRFVFWCSSA-N (1s,2r)-1-(3-fluorophenyl)-3-(methylamino)-1-[(2s)-2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl]propan-2-ol Chemical compound C1([C@H]2CN(C3=CC=CC=C3O2)[C@H]([C@H](O)CNC)C=2C=C(F)C=CC=2)=CC=CC=C1 DAQQEUNYRWDGFD-JRFVFWCSSA-N 0.000 claims 1
- JARDVEIUNTUOPU-AEFFLSMTSA-N (1s,2r)-1-(6-chloro-2,3-dihydro-1,4-benzoxazin-4-yl)-1-(3,5-difluorophenyl)-3-(methylamino)propan-2-ol Chemical compound C1([C@H](N2C3=CC(Cl)=CC=C3OCC2)[C@H](O)CNC)=CC(F)=CC(F)=C1 JARDVEIUNTUOPU-AEFFLSMTSA-N 0.000 claims 1
- POXIKNMZDSNTEK-AEFFLSMTSA-N (1s,2r)-1-(6-chloro-2,3-dihydro-1,4-benzoxazin-4-yl)-3-(methylamino)-1-phenylpropan-2-ol Chemical compound C1([C@H](N2C3=CC(Cl)=CC=C3OCC2)[C@H](O)CNC)=CC=CC=C1 POXIKNMZDSNTEK-AEFFLSMTSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- ZXWNVYVRSLCDLQ-UHFFFAOYSA-N 1-(2,2-dimethyl-3h-1,4-benzoxazin-4-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol Chemical compound C1C(C)(C)OC2=CC=CC=C2N1C(C(O)CNC)C1=CC=CC(F)=C1 ZXWNVYVRSLCDLQ-UHFFFAOYSA-N 0.000 claims 1
- CUYWGZURXSNKCO-UHFFFAOYSA-N 1-(2,2-dimethyl-3h-1,4-benzoxazin-4-yl)-3-(methylamino)-1-phenylpropan-2-ol Chemical compound C1C(C)(C)OC2=CC=CC=C2N1C(C(O)CNC)C1=CC=CC=C1 CUYWGZURXSNKCO-UHFFFAOYSA-N 0.000 claims 1
- GEBVDAMYWOGQQG-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzothiazin-4-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol Chemical compound C1CSC2=CC=CC=C2N1C(C(O)CNC)C1=CC=CC(F)=C1 GEBVDAMYWOGQQG-UHFFFAOYSA-N 0.000 claims 1
- GRMKZDGSGRMPAR-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-(methylamino)-1-(2-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)propan-2-ol Chemical compound C1C(C)OC2=CC=CC=C2N1C(C(O)CNC)C1=CC=CC(F)=C1 GRMKZDGSGRMPAR-UHFFFAOYSA-N 0.000 claims 1
- DAQQEUNYRWDGFD-UHFFFAOYSA-N 1-(3-fluorophenyl)-3-(methylamino)-1-(2-phenyl-2,3-dihydro-1,4-benzoxazin-4-yl)propan-2-ol Chemical compound C=1C=CC(F)=CC=1C(C(O)CNC)N(C1=CC=CC=C1O1)CC1C1=CC=CC=C1 DAQQEUNYRWDGFD-UHFFFAOYSA-N 0.000 claims 1
- JARDVEIUNTUOPU-UHFFFAOYSA-N 1-(6-chloro-2,3-dihydro-1,4-benzoxazin-4-yl)-1-(3,5-difluorophenyl)-3-(methylamino)propan-2-ol Chemical compound C1COC2=CC=C(Cl)C=C2N1C(C(O)CNC)C1=CC(F)=CC(F)=C1 JARDVEIUNTUOPU-UHFFFAOYSA-N 0.000 claims 1
- AGJPPNRFILLTJO-UHFFFAOYSA-N 1-(6-chloro-2,3-dihydro-1,4-benzoxazin-4-yl)-1-(3-fluorophenyl)-3-(methylamino)propan-2-ol Chemical compound C1COC2=CC=C(Cl)C=C2N1C(C(O)CNC)C1=CC=CC(F)=C1 AGJPPNRFILLTJO-UHFFFAOYSA-N 0.000 claims 1
- DIGQLIDYCCXZRH-UHFFFAOYSA-N 3-(methylamino)-1-(4-methyl-2,3-dihydroquinoxalin-1-yl)-1-phenylpropan-2-ol Chemical compound C1CN(C)C2=CC=CC=C2N1C(C(O)CNC)C1=CC=CC=C1 DIGQLIDYCCXZRH-UHFFFAOYSA-N 0.000 claims 1
- PNUHFKKBYWHRPC-UHFFFAOYSA-N 3-(methylamino)-1-(6-methyl-2,3-dihydro-1,4-benzoxazin-4-yl)-1-phenylpropan-2-ol Chemical compound C1COC2=CC=C(C)C=C2N1C(C(O)CNC)C1=CC=CC=C1 PNUHFKKBYWHRPC-UHFFFAOYSA-N 0.000 claims 1
- UJJOBWRSFTXKRE-UHFFFAOYSA-N 3-(methylamino)-1-phenyl-1-[4-(2,2,2-trifluoroethyl)-2,3-dihydroquinoxalin-1-yl]propan-2-ol Chemical compound C1CN(CC(F)(F)F)C2=CC=CC=C2N1C(C(O)CNC)C1=CC=CC=C1 UJJOBWRSFTXKRE-UHFFFAOYSA-N 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical group NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical group NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 208000017283 Bile Duct disease Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010064012 Central pain syndrome Diseases 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- JJHHIJFTHRNPIK-UHFFFAOYSA-N Diphenyl sulfoxide Chemical group C=1C=CC=CC=1S(=O)C1=CC=CC=C1 JJHHIJFTHRNPIK-UHFFFAOYSA-N 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 206010065016 Post-traumatic pain Diseases 0.000 claims 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000036319 cervical spondylosis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical group C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000005801 spondylosis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 208000012720 thalamic disease Diseases 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55783104P | 2004-03-30 | 2004-03-30 | |
| US56986104P | 2004-05-11 | 2004-05-11 | |
| US11/091,291 US7414052B2 (en) | 2004-03-30 | 2005-03-28 | Phenylaminopropanol derivatives and methods of their use |
| PCT/US2005/010510 WO2005097761A1 (en) | 2004-03-30 | 2005-03-29 | Heterocyclic phenylaminopropanol derivatives as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (vms) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007531750A JP2007531750A (ja) | 2007-11-08 |
| JP2007531750A5 true JP2007531750A5 (https=) | 2008-05-22 |
Family
ID=34964470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007506468A Withdrawn JP2007531750A (ja) | 2004-03-30 | 2005-03-29 | 血管運動症状（ｖｍｓ）を治療するためのモノアミン再取り込みの調節剤としての複素環式フェニルアミノプロパノール誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7414052B2 (https=) |
| EP (1) | EP1730127B1 (https=) |
| JP (1) | JP2007531750A (https=) |
| AR (1) | AR048447A1 (https=) |
| AT (1) | ATE399158T1 (https=) |
| AU (1) | AU2005230899A1 (https=) |
| BR (1) | BRPI0509513A (https=) |
| CA (1) | CA2560966A1 (https=) |
| DE (1) | DE602005007718D1 (https=) |
| PA (1) | PA8628101A1 (https=) |
| PE (1) | PE20060163A1 (https=) |
| TW (1) | TW200538460A (https=) |
| WO (1) | WO2005097761A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| WO2005118539A1 (en) * | 2004-06-01 | 2005-12-15 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| BRPI0616459A2 (pt) * | 2005-09-29 | 2011-06-21 | Wyeth Corp | compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto |
| PE20080655A1 (es) * | 2006-08-24 | 2008-07-14 | Wyeth Corp | Proceso para preparar derivados de indolinona fenilaminopropanol |
| WO2008042362A1 (en) * | 2006-10-04 | 2008-04-10 | Wyeth | Arylamino-arylpropanolamine derivatives and methods of their use |
| CL2007003591A1 (es) * | 2006-12-12 | 2008-02-29 | Wyeth Corp | Compuestos derivados de sulfonamida ciclicos, inhibidores de retoma de monoamina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de disfuncion sexual, trastorno gastrointestinal, trastorno genitourinari |
| CL2008001563A1 (es) * | 2007-05-30 | 2008-10-10 | Wyeth6 3 | Compuestos derivados de benzodioxanos condensados con heterociclos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, crisis de panico, entre otras. |
| CN102573836A (zh) * | 2009-06-10 | 2012-07-11 | 雅培股份有限两合公司 | 取代的羟吲哚衍生物治疗和预防疼痛的应用 |
| RU2598842C2 (ru) * | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3454554A (en) * | 1960-10-14 | 1969-07-08 | Colgate Palmolive Co | Aminoalkyliminodibenzyl compounds |
| US4123543A (en) * | 1971-09-16 | 1978-10-31 | Ab Kabi | Derivatives of substituted indoline lactans with effect on the central nervous system |
| CS175831B1 (https=) | 1974-12-17 | 1977-05-31 | ||
| IL56369A (en) * | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
| US4310524A (en) * | 1980-04-11 | 1982-01-12 | Richardson-Merrell, Inc. | TCA Composition and method for rapid onset antidepressant therapy |
| PH18686A (en) | 1981-05-26 | 1985-08-29 | Merck & Co Inc | 1-(3 halo-2-pyridinyl) piperazine |
| US4535186A (en) * | 1983-04-19 | 1985-08-13 | American Home Products Corporation | 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives |
| EP0135905A3 (de) | 1983-09-29 | 1986-10-22 | ASTA Pharma Aktiengesellschaft | Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane |
| ZA864772B (en) | 1985-07-02 | 1987-02-25 | Merrell Dow Pharma | Novel chemical compounds |
| CA1327795C (en) | 1987-08-14 | 1994-03-15 | Jules Freedman | Antidepressants which are aryloxy inadanamines |
| US4826844A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols |
| CA2083698C (en) | 1990-06-01 | 1997-11-04 | Albert A. Carr | (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
| US5648511A (en) * | 1990-11-19 | 1997-07-15 | G.D. Searle & Co. | Method for making intermediates useful in the synthesis of retroviral protease inhibitors |
| FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5502047A (en) * | 1993-03-22 | 1996-03-26 | Kavey; Neil B. | Treatment for insomnia |
| US5516774A (en) * | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| FR2714378B1 (fr) | 1993-12-24 | 1996-03-15 | Sanofi Sa | Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant. |
| AU3414295A (en) | 1994-08-19 | 1996-03-14 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
| EP0743064A1 (en) | 1995-05-17 | 1996-11-20 | Eli Lilly And Company | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease |
| FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
| GB9606016D0 (en) * | 1996-03-22 | 1996-05-22 | Smithkline Beecham Plc | Novel use |
| UA48219C2 (uk) | 1996-03-25 | 2002-08-15 | Елі Ліллі Енд Компані | Композиція для вгамування болю (варіанти) та спосіб вгамування болю |
| WO1998014208A1 (en) | 1996-09-30 | 1998-04-09 | President And Fellows Of Harvard College | Reactive ligands and covalent ligand-protein complexes |
| FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU3306399A (en) | 1998-03-02 | 1999-09-20 | Eli Lilly And Company | Fluoxetine hydrochloride for decreasing hot flashes |
| TW528754B (en) | 1998-04-29 | 2003-04-21 | Wyeth Corp | Indolyl derivatibes as serotonergic agents |
| WO2000002551A2 (en) | 1998-07-13 | 2000-01-20 | Nps Pharmaceuticals, Inc. | Methods and compounds for treating depression |
| PL350924A1 (en) | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
| DE60022692T2 (de) | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
| FR2804115B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| FR2804114B1 (fr) | 2000-01-25 | 2002-03-08 | Sanofi Synthelabo | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| EP1272483A2 (en) | 2000-03-24 | 2003-01-08 | Millenium Pharmaceuticals, Inc. | OXINDOLE INHIBITORS OF FACTOR Xa |
| US20030008860A1 (en) * | 2002-05-09 | 2003-01-09 | Bakker-Arkema Rebecca Guggemos | Treatment of congestive heart failure |
| GB2362826A (en) | 2000-06-02 | 2001-12-05 | Lilly Co Eli | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| EP1318988A2 (en) | 2000-09-11 | 2003-06-18 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| AU2002250058B2 (en) | 2001-02-12 | 2007-08-16 | Wyeth Llc | Novel succinate salt of O-desmethyl-venlafaxine |
| CA2442410A1 (en) | 2001-03-29 | 2002-10-10 | Owen Brendan Wallace | Duloxetine for treatment of hot flashes |
| EP1266659A1 (en) | 2001-06-11 | 2002-12-18 | Pantarhei Bioscience B.V. | Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes |
| US6903110B2 (en) | 2001-07-25 | 2005-06-07 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene |
| US6794385B2 (en) * | 2001-08-08 | 2004-09-21 | Pharmacia & Upjohn, S.P.A. | Benzoxazine derivatives useful as integrin receptor antagonists |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| WO2003037334A1 (en) | 2001-10-31 | 2003-05-08 | Merck & Co., Inc. | Method for treating or preventing symptoms of hormonal variation including hot flashes |
| US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| CA2479350A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| KR20050049476A (ko) | 2002-08-14 | 2005-05-25 | 파마시아 앤드 업존 캄파니 엘엘씨 | 홍조를 치료하기 위한 레복세틴의 용도 |
| US20040180879A1 (en) * | 2002-10-15 | 2004-09-16 | Deecher Darlene Coleman | Novel method of treating vasomotor symptoms |
| US7345096B2 (en) * | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US20040152710A1 (en) * | 2002-10-15 | 2004-08-05 | Deecher Darlene Coleman | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| US7491723B2 (en) * | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
| US7550485B2 (en) * | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
| US7524846B2 (en) * | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
| US7419980B2 (en) * | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
| US20050130987A1 (en) * | 2003-10-14 | 2005-06-16 | Wyeth | Methods of treating vasomotor symptoms |
| US7365076B2 (en) * | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
| US7531543B2 (en) * | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
| US20050165082A1 (en) * | 2003-12-16 | 2005-07-28 | Wyeth | Methods of treating vasomotor symptoms |
| US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
-
2005
- 2005-03-28 US US11/091,291 patent/US7414052B2/en not_active Expired - Fee Related
- 2005-03-29 TW TW094109686A patent/TW200538460A/zh unknown
- 2005-03-29 DE DE602005007718T patent/DE602005007718D1/de not_active Expired - Fee Related
- 2005-03-29 AT AT05730979T patent/ATE399158T1/de not_active IP Right Cessation
- 2005-03-29 CA CA002560966A patent/CA2560966A1/en not_active Abandoned
- 2005-03-29 WO PCT/US2005/010510 patent/WO2005097761A1/en not_active Ceased
- 2005-03-29 JP JP2007506468A patent/JP2007531750A/ja not_active Withdrawn
- 2005-03-29 EP EP05730979A patent/EP1730127B1/en not_active Expired - Lifetime
- 2005-03-29 AU AU2005230899A patent/AU2005230899A1/en not_active Abandoned
- 2005-03-29 BR BRPI0509513-1A patent/BRPI0509513A/pt not_active IP Right Cessation
- 2005-03-30 AR ARP050101207A patent/AR048447A1/es unknown
- 2005-03-30 PA PA20058628101A patent/PA8628101A1/es unknown
- 2005-03-30 PE PE2005000366A patent/PE20060163A1/es not_active Application Discontinuation
-
2008
- 2008-06-23 US US12/144,363 patent/US7638512B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007516941A5 (https=) | ||
| JP2004519438A5 (https=) | ||
| JP2008531714A (ja) | 不安障害の治療用及び／又は予防用の医薬組成物 | |
| JP2008538741A (ja) | 鬱病の治療用及び／又は予防用の医薬組成物 | |
| JP2007508360A5 (https=) | ||
| JP2010514829A5 (https=) | ||
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| CN1711085A (zh) | 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 | |
| JP2004534816A5 (https=) | ||
| JP2019519587A5 (https=) | ||
| AR069260A1 (es) | Compuesto 1-[2-(2, 4-dimetilfenilsulfanil)fenil]piperazina.usos terapeuticos de compuestos que tienen actividad combinada de sert (transportador de serotonina), 5-ht3 (receptor 3 de 5-hidroxitriptamina) y 5-ht1a (receptor 1a de 5-hidroxitriptamina).metodo de tratamiento. | |
| CN1468111A (zh) | 治疗急性、慢性疼痛和/或神经病性疼痛和偏头痛的药物组合物 | |
| JP2007531750A5 (https=) | ||
| JP2015531764A5 (https=) | ||
| JP2013509441A5 (https=) | ||
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| JP2012531402A5 (https=) | ||
| JP2007531751A5 (ja) | 血管運動症状（ｖｍｓ）の治療のためのノルエピネフリン（ｎｅ）およびセロトニン（５−ｈｔ）活性およびモノアミン再取り込みの調節物質としてのヘテロサイクリックフェニルプロパン−２−オール誘導体および関連化合物 | |
| RU2004139041A (ru) | Применение гетероаренкарбоксамидов в качестве дофамин-d3 лигандов для лечения заболеваний центральной нервной системы | |
| JP2005538974A5 (https=) | ||
| JP2024511057A5 (https=) | ||
| JP2019535715A5 (https=) | ||
| JP2008542414A5 (https=) | ||
| JP2009510095A5 (https=) | ||
| JP2008523100A5 (https=) |